These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33016157)

  • 1. Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse.
    Balsat M; Cacheux V; Carre M; Tavernier-Tardy E; Thomas X
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):879-891. PubMed ID: 33016157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
    Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F
    Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
    De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
    BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
    Assi R; Kantarjian H; Short NJ; Daver N; Takahashi K; Garcia-Manero G; DiNardo C; Burger J; Cortes J; Jain N; Wierda W; Chamoun S; Konopleva M; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):897-901. PubMed ID: 28927784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
    Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
    Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia.
    Wu X; Lu S; Zhang X; Yang Z; Sun A; Wu D; Zhou H; Miao M
    Cancer Med; 2024 Sep; 13(17):e70161. PubMed ID: 39240182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
    Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
    Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
    Yilmaz M; Kantarjian H; Ravandi-Kashani F; Short NJ; Jabbour E
    Clin Adv Hematol Oncol; 2018 Mar; 16(3):216-223. PubMed ID: 29742077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
    Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
    Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
    J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of E255K/V-inclusive mutations in a Philadelphia-positive acute lymphoblastic leukemia with mutation evolution during sequential TKIs therapies: A case report.
    Zhao M; Gui X; Wu Q; Xia L; Wang Y
    Medicine (Baltimore); 2021 May; 100(18):e25579. PubMed ID: 33950935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Abou Dalle I; Jabbour E; Short NJ; Ravandi F
    Curr Treat Options Oncol; 2019 Jan; 20(1):4. PubMed ID: 30675645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.
    Fan S; Wang L; Lu Y; Li Z
    Ann Hematol; 2024 Feb; 103(2):525-532. PubMed ID: 37940719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens.
    Xiong ZY; Shen YJ; Zhang SZ; Zhu HH
    Hematology; 2024 Dec; 29(1):2335856. PubMed ID: 38581291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
    Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
    Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.
    Thomas X; Heiblig M
    Expert Opin Drug Discov; 2016 Nov; 11(11):1061-1070. PubMed ID: 27548716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
    Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
    Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.